To determine whether Ola reduces the targets of the ph-S675-β-catenin-CEGRs/ALCDs pathway in PDXs, we examined the GPC3 and AFP levels in the tumor tissues of PDXs (n = 6) from three HBL patients treated with vehicle (control) or with Ola. The gene discussed is GPC3; the disease is neoplasm.